英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
531648查看　531648　在百度字典中的解释百度英翻中〔查看〕
531648查看　531648　在Google字典中的解释Google英翻中〔查看〕
531648查看　531648　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ZORYVE® (roflumilast) | Official Patient Website
    ZORYVE foam is a prescription medicine used on the skin (topical) to treat plaque psoriasis of the scalp and body in adults and children 12 years of age and older
  • Review - Food and Drug Administration
    Zoryve (roflumilast) topical cream 3% was approved on July 29, 2022, under NDA 215985 and is indicated for the treatment of plaque psoriasis, including intertriginous areas, in patients 12
  • Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis . . .
    Investigational ZORYVE® (roflumilast) cream 0 05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four
  • DailyMed - ZORYVE- roflumilast aerosol, foam
    ZORYVE (roflumilast) topical foam, 0 3%, is a white to off-white foam for topical use The active ingredient, roflumilast, is a phosphodiesterase 4 (PDE4) inhibitor
  • FDA approves topical foam for plaque psoriasis of the scalp and body
    The U S Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0 3% for the treatment of plaque psoriasis of the scalp and body in adult and
  • ARQT Press Release: Arcutis Presents New Phase 2 Results in Infan. . .
    Globe Newswire 28-Mar-2026 11:00 AM Investigational ZORYVE® (roflumilast) cream 0 05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as
  • FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE . . .
    About ZORYVE® (roflumilast) ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined—atopic dermatitis, seborrheic dermatitis, and plaque psoriasis ZORYVE cream is a topical formulation of roflumilast, an advanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor
  • Arcutis Presents New Phase 2 Results in Infants with Atopic Derm
    Investigational ZORYVE® (roflumilast) cream 0 05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of
  • Arcutis Unveils Phase 2 Results for Atopic Dermatitis - ARQT | Bi
    Arcutis reveals Phase 2 trial results for ZORYVE cream in infants with atopic dermatitis, showing significant symptom reduction and rapid itch relief
  • NDA BLA Multi‐Disciplinary Review and Evaluation
    Zoryve (roflumilast foam, 0 3%) is a phosphodiesterase‐4 (PDE‐4) inhibitor developed by the Applicant under IND 142047 for the indication of topical treatment of seborrheic dermatitis (SD)





中文字典-英文字典  2005-2009